Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 148

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1
Chunk 148
---
Nominating
Committee

Our
Nominating Committee’s responsibilities include:

    ●
    identifying
    individuals qualified to become Board members;

    ●
    recommending to the Board
    the persons to be nominated for election as directors and to each Board committee;

    ●
    reviewing with the Chief
    Executive Officer and making recommendations to the Board with respect to our succession plans for the Chief Executive Officer and
    other executive officers;

    ●
    reviewing and making recommendations
    to the Board the composition and chairperson of each Board committee; and

    ●
    overseeing the evaluation
    of the Board and its committees.

The
Nominating Committee charter is available on the Investors page of our website at www.indaptusrx.com. The members of our Nominating
Committee are Ms. Karah and Mr. Maddaluna. Ms. Karah serves as the Chairperson of the Nominating Committee. The Nominating Committee
has the authority to consult with outside advisors or retain search firms to assist in the search for qualified candidates or consider
director candidates recommended by our stockholders.

79

Science
and Technology Committee

Our
Science and Technology Committee’s responsibilities include:

    ●
    reviewing and
    advising on our drug development strategy, including the selection of therapeutic targets, the design and execution of clinical trials,
    and the regulatory pathway for approval;

    ●
    assessing our research
    pipeline and recommending changes or improvements to ensure a sustainable and diverse portfolio of drug candidates;

    ●
    evaluating our intellectual
    property strategy and overseeing the implementation of appropriate measures to protect our discoveries and inventions; and

    ●
    reviewing our manufacturing
    strategy and overseeing the quality controls put in place to meet regulatory requirements.

The
members of our Science and Technology Committee are Dr. Gilbert, Mr. Maddaluna, Dr. Martell, and Mr. Newman. Mr. Newman serves as the
Chairperson of the Science and Technology Committee.

Item
11. Executive Compensation.

Our
named executive officers for 2024, which consist of our principal executive officer and the next two most-highly compensated executive
officers who were serving as executive officers as of December 31, 2024 are:

    ●
    Jeffrey A.
    Meckler, Chief Executive Officer and Director;

    ●
    Walt. A. Linscott, Esq.,
    Chief Operating Officer; and